Palatin dry eyes trial misses endpoints

 

• On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met, Statistical Significance (P<0.025)

  • Multiple Secondary Symptom Endpoints Met, Statistical Significance (P<0.025)

• On an Intent-to-Treat Analysis, Co-Primary Sign Endpoint and Secondary Sign Endpoints Not Met

  • PL9643 Demonstrated Superiority Over Vehicle in Multiple Sign Endpoints

• Excellent Safety and Tolerability Profile

• Future Discussions Planned with FDA Regarding Regulatory Approval Path

https://finance.yahoo.com/news/palatin-announces-results-pl9643-melody-123000604.html